Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids
ReviewLipoprotein lipase mediated fatty acid delivery and its impact in diabetic cardiomyopathy☆
Highlights
► LPL is a key provider of fatty acids to the heart following diabetes. ► We describe mechanisms by which vascular LPL is regulated following diabetes. ► Perturbations in LPL contribute to the pathology of diabetic cardiomyopathy.
Introduction
During diabetes, when cardiac glucose utilization is impaired, the heart switches to exclusively using FA for energy supply [1]. This metabolic switching could lead to cardiomyocyte cell death, and eventually heart disease [1]. One mechanism for providing the heart with FA is LPL. LPL, synthesized in cardiomyocytes, is transferred to endothelial cells lining the vascular lumen, where it catalyzes the breakdown of lipoprotein-triglyceride (TG) to provide FA to the heart [2]. Following diabetes, LPL activity at the coronary lumen increases by mechanisms that have yet to be completely elucidated. This review discusses how, following diabetes, the heart adapts to reduced glucose uptake and oxidation by increasing FA delivery (from LPL-catalyzed degradation of TG-rich lipoproteins), and hence utilization. Specifically, we will focus on the mechanisms that alter LPL, and the consequences of this augmented LPL-derived FA on cardiac function. Understanding the regulation of cardiac LPL will allow to us lower FA delivery to the heart, and develop strategies to overcome contractile dysfunction following diabetes.
Section snippets
Heart disease in diabetes
Heart disease is a leading cause of death in diabetic patients, with coronary vessel disease and atherosclerosis being primary reasons for the increased incidence of cardiovascular dysfunction [3], [4]. However, a predisposition to heart failure might also reflect the effects of underlying abnormalities in diastolic function that can be detected in asymptomatic patients with Type 1 (T1D) and Type 2 (T2D) diabetes alone [5], [6]. These observations suggest a specific impairment of heart muscle
Cardiac metabolism
As uninterrupted contraction is a unique feature of the heart, cardiac muscle has a high demand for provision of energy in the form of ATP [22]. Under normal physiological conditions, this energy is obtained via the oxidation of an assortment of different substrates including lactate, ketone bodies, glucose and FA [23], [24]. Interestingly, the heart can rapidly switch its substrate selection to accommodate different physiological and pathophysiological conditions involving altered
Substrate availability during diabetes
Glucose and lipids are the major substrates affected by diabetes. Hyperglycemia is a consequence of decreased glucose clearance and augmented hepatic glucose production, whereas enhanced lipolysis in adipose tissue and higher lipoprotein synthesis in the liver dramatically increases circulating free FA and TG [35], [36]. These fuels are made available to the cardiomyocyte through a wide array of mechanisms.
Heart LPL in human diabetes
In vascular tissue, LPL is bound to heparan sulfate proteoglycans (HSPG) and glycosylphosphatidylinositol-anchored high density lipoprotein binding protein 1 (GPIHBP1) through ionic linkage (Fig. 1); LPL has abundant positively charged domains [48]. HSPG are ubiquitous macromolecules present on cell membranes and extracellular matrix, and consist of a core protein to which several linear heparan sulfate (HS) side chains are covalently linked [49], [50]. They serve, not only as structural
Enzyme dimerization
Catalytically active LPL is a homodimer, with two inactive monomers attached non-covalently in a head-to-tail fashion [84]. Thus, after LPL mRNA is translated as an inactive polypeptide, the monomeric enzyme requires processing to attain activity, an event that occurs in the endoplasmic reticulum (ER) and involves multiple steps [85], [86]. This includes glycosylation, subsequent trimming of glucose residues in the oligosaccharides, and binding to chaperones like calreticulin/calnexin and
LPL and cardiomyopathy
A number of studies have shown that excessive FA induces lipotoxicity and contributes to the development of cardiomyopathy through over production of reactive oxygen species (as a consequence of high rate of FA oxidation) [132], accumulation of TG (when FA uptake supersedes its oxidation) [133], [134], [135], and generation of ceramide (an intracellular messenger known to trigger apoptosis) [133], [136], [137]. Thus, cardiac-specific overexpression of FA transport protein 1 significantly
Conclusion
In patients with diabetes, an increased risk of symptomatic heart failure usually develops in the presence of hypertension or ischemic heart disease [146]. However, a predisposition to heart failure might also reflect the effects of underlying abnormalities in diastolic function that can occur in asymptomatic patients with diabetes alone (termed diabetic cardiomyopathy). We suggest that following diabetes and compromised glucose utilization, recruitment of LPL to the cardiomyocyte cell surface
Acknowledgements
This study was supported by an operating grant from the Canadian Diabetes Association and the CIHR. Minsuk Kim was a recipient of a doctoral research award from Heart and Stroke Foundation of Canada and the Canadian Diabetes Association and more recently, a PDF from the Heart and Stroke Foundation of Canada.
References (146)
- et al.
Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitus
Am. J. Cardiol.
(2004) - et al.
Left ventricular systolic and diastolic functional abnormalities in asymptomatic patients with non-insulin-dependent diabetes mellitus
J. Am. Soc. Echocardiogr.
(2001) - et al.
Vascular endothelial dysfunction in diabetic cardiomyopathy: pathogenesis and potential treatment targets
Pharmacol. Ther.
(2006) - et al.
Alterations in ion channel physiology in diabetic cardiomyopathy
Endocrinol. Metab. Clin. N. Am.
(2006) - et al.
Leptin activates cardiac fatty acid oxidation independent of changes in the AMP-activated protein kinase-acetyl-CoA carboxylase-malonyl-CoA axis
J. Biol. Chem.
(2002) - et al.
Myocardial substrate metabolism: implications for diabetic cardiomyopathy
J. Mol. Cell. Cardiol.
(1995) - et al.
PPAR signaling in the control of cardiac energy metabolism
Trends Cardiovasc. Med.
(2000) - et al.
Metabolic switch and hypertrophy of cardiomyocytes following treatment with angiotensin II are prevented by AMP-activated protein kinase
J. Biol. Chem.
(2008) - et al.
Insulin and contraction stimulate exocytosis, but increased AMP-activated protein kinase activity resulting from oxidative metabolism stress slows endocytosis of GLUT4 in cardiomyocytes
J. Biol. Chem.
(2005) - et al.
The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight
Atherosclerosis
(2010)
Effects of nonlipolytic ligand function of endothelial lipase on high density lipoprotein metabolism in vivo
J. Biol. Chem.
Release of lipoprotein lipase and hepatic triglyceride lipase in rats by heparin and other sulphated polysaccharides
Thromb. Res.
Evidence for rapid “metabolic switching” through lipoprotein lipase occupation of endothelial-binding sites
J. Mol. Cell. Cardiol.
The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding
Metabolism
Contribution of hyperinsulinemia to modulation of lipoprotein lipase activity in the obese Zucker rat
Metabolism
Streptozotocin-induced diabetes in human apolipoprotein B transgenic mice. Effects on lipoproteins and atherosclerosis
J. Lipid Res.
Insulin-mediated modifications of myocardial lipoprotein lipase and lipoprotein metabolism
J. Biol. Chem.
Rapid subunit exchange in dimeric lipoprotein lipase and properties of the inactive monomer
J. Biol. Chem.
Transcriptional regulation of the human lipoprotein lipase gene in 3T3-L1 adipocytes
J. Biol. Chem.
Calreticulin promotes folding/dimerization of human lipoprotein lipase expressed in insect cells (sf21)
J. Biol. Chem.
Cellular and secreted lipoprotein lipase revisited
Clin. Biochem.
Regulation of lipoprotein lipase by protein kinase C alpha in 3T3-F442A adipocytes
J. Biol. Chem.
HSP25 inhibits protein kinase C delta-mediated cell death through direct interaction
J. Biol. Chem.
The vesicle- and target-SNARE proteins that mediate Glut4 vesicle fusion are localized in detergent-insoluble lipid rafts present on distinct intracellular membranes
J. Biol. Chem.
Protein kinase D 3 is localized in vesicular structures and interacts with vesicle-associated membrane protein 2
Cell. Signal.
Protein kinase D intracellular localization and activity control kinase D-interacting substrate of 220-kDa traffic through a postsynaptic density-95/discs large/zonula occludens-1-binding motif
J. Biol. Chem.
Role of changes in cardiac metabolism in development of diabetic cardiomyopathy
Am. J. Physiol. Heart Circ. Physiol.
Cardiac lipoprotein lipase: metabolic basis for diabetic heart disease
Cardiovasc. Res.
Association of diabetes mellitus with coronary atherosclerosis and myocardial lesions. An autopsy study from the Honolulu Heart Program
Am. J. Epidemiol.
A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation
Nat. Med.
Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy
Cardiology
Diabetic cardiomyopathy
Diabetes Care
Diastolic dysfunction in normotensive men with well-controlled type 2 diabetes: importance of maneuvers in echocardiographic screening for preclinical diabetic cardiomyopathy
Diabetes Care
Diabetes and idiopathic cardiomyopathy: a nationwide case–control study
Diabetes Care
Left ventricular diastolic dysfunction in type 2 diabetes mellitus model rats
Am. J. Physiol. Heart Circ. Physiol.
Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications
Endocr. Rev.
Metabolic disturbances in diabetic cardiomyopathy
Mol. Cell. Biochem.
Diabetic cardiomyopathy: recent evidence from mouse models of type 1 and type 2 diabetes
Can. J. Physiol. Pharmacol.
Cardiac alpha- and beta-adrenergic receptor alterations in diabetic cardiomyopathy
Basic Res. Cardiol.
A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes
Circ. Res.
Metabolic modulation: a means to mend a broken heart
Circulation
The diabetic heart: metabolic causes for the development of a cardiomyopathy
Cardiovasc. Res.
Myocardial insulin resistance and cardiac complications of diabetes
Curr. Drug Targets Immune Endocr. Metab. Disord.
Cardiac energy metabolism: models of cellular respiration
Annu. Rev. Biomed. Eng.
Effect of ketone bodies on cardiac metabolism
Am. J. Physiol.
Cardiac fatty acid uptake and transport in health and disease
Cardiovasc. Res.
Regulation of energy substrate metabolism in the diabetic heart
Cardiovasc. Res.
Adaptation and maladaptation of the heart in diabetes: Part II: Potential mechanisms
Circulation
Energy metabolism in the hypertrophied heart
Heart Fail. Rev.
Energy substrate metabolism in cardiac hypertrophy
Curr. Hypertens. Rep.
Cited by (41)
Revealment study on the regulation of lipid metabolism by Lingguizhugan Decoction in heart failure treatment based on integrated lipidomics and proteomics
2023, Biomedicine and PharmacotherapyCitation Excerpt :In previous studies, researchers have demonstrated that plasma FAs concentrations were independently associated with incident HF [38–40]. High concentration of FAs leads to decreased myocardial glucose uptake and oxidation, increased fatty acid oxidation, as well as altered cardiomyocyte gene expression [41]. Unfortunately, the persistently altered supply and utilization of FAs would result in enhanced mitochondrial ROS generation and oxidative stress which led to heart failure ultimately.
Changes in Lipoprotein Lipase in the Heart Following Diabetes Onset
2023, EngineeringCitation Excerpt :When present in excess, FAs are diverted from adipocytes to alternative organs, including the heart. One unfortunate consequence of this effect is that FAs can trigger a decrease in cardiac efficiency, low glucose oxidation rates, structural impairments, and cellular demise [9,18–20,65]. In this regard, when LPL is specifically overexpressed in the heart, more FAs are provided, which has been reported to cause severe muscle defects including cardiomyocyte apoptosis, as well as reduced function in the absence of vascular changes—a situation comparable to DCM [23,24].
Plasma tumour and metabolism related biomarkers AMBP, LPL and Glyoxalase I differentiate heart failure with preserved ejection fraction with pulmonary hypertension from pulmonary arterial hypertension
2021, International Journal of CardiologyCitation Excerpt :In HF, however, deranged metabolism of energy substrates occurs, leading to a shift from fatty acid to glucose utilization [32]. In the heart, LPL is mainly synthesized by cardiomyocytes and is subsequently translocated to the apical surfaces of vascular endothelial cells [33]. LPL expression is regulated by hormonal and inflammatory stimuli such as insulin, FGF and transforming growth factor-β [31].
Disruption of energy utilization in diabetic cardiomyopathy; a mini review
2020, Current Opinion in PharmacologyCitation Excerpt :Chronic increases in both insulin and circulating FA are accompanied by increased expression and activation of proteins involved in FA uptake in the heart, such as the fatty acid translocase CD36 and fatty acid binding proteins (FABP) [7,40]. In addition, overexpression of other proteins involved with FA uptake such as long-chain acyl-CoA synthetase and lipoprotein lipase contribute to excess accumulation of triglycerides and lipotoxicity in DCM [40,43]. FA are endogenous ligands of the transcription factor peroxisome proliferator-activated receptors (PPARs) family (PPAR-α, PPARβ/PPAR-δ, and PPAP-γ,) [11,40,44].
Abnormal Myocardial Dietary Fatty Acid Metabolism and Diabetic Cardiomyopathy
2018, Canadian Journal of CardiologyAdriamycin-induced cardiomyopathy can serve as a model for diabetic cardiomyopathy – a hypothesis
2017, Asian Pacific Journal of Tropical Biomedicine
- ☆
This article is part of a Special Issue entitled Triglyceride Metabolism and Disease.